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Barcelona, SpainABSTRACT Eosinophil cationic protein (ECP) is a highly stable, cytotoxic ribonuclease with the ability to enter and disrupt
membranes that participates in innate immune defense against parasites but also kills human cells. We have used NMR spec-
troscopy to characterize the binding of ECP to membrane and heparin mimetics at a residue level. We believe we have identiﬁed
three Arg-rich surface loops and Trp35 as crucial for membrane binding. Importantly, we have provided evidence that the inter-
action surface of ECP with heparin mimetics is extended with respect to that previously described (fragment 34–38). We believe
we have identiﬁed new sites involved in the interaction for the ﬁrst time, and shown that the N-terminal a-helix, the third loop, and
the ﬁrst and last b-strands are key for heparin binding. We have also shown that a biologically active ECP N-terminal fragment
comprising the ﬁrst 45 residues (ECP1–45) retains the capacity to bind membrane and heparin mimetics, thus neither the ECP
tertiary structure nor its high conformational stability are required for cytotoxicity.INTRODUCTIONEosinophil cationic protein (ECP, known also as human ribo-
nuclease 3) is present in large amounts in eosinophil granules.
The 3D structure of this 133-residue protein, has been deter-
mined with (1) and without ligands by x-ray crystallography
(2,3), and recently by NMR spectroscopic methods (4)
(Fig. 1). The tertiary structure of ECP closely resembles that
of bovine pancreatic ribonuclease A (RNase A) (5), although
the loops in ECP are significantly longer. ECP is quite rich in
Arg and Pro residues (19 and 12, respectively). ECP has two
Trp residues one of which, at position 35, is hyperexposed.
ECP is released by activated eosinophils and at low levels
by activated neutrophils (6), and plays a role in host defense
against parasites such as helminths (7,8). ECP also inacti-
vates virus (9) and kills both Gram-negative and Gram-posi-
tive bacteria at low mM concentrations (10,11). However,
ECP can be regarded as a double-edged sword as it is toxic
to host epithelial tissues (12,13). In fact, ECP is implicated in
asthma (14), the most common childhood disease in devel-
oped countries (15). ECP levels in the blood are well corre-
lated with asthma severity and are used widely to monitor the
effectiveness of asthma treatments (16).
We are interested in understanding the molecular basis of
ECP activities. Previous studies have established that the
cytotoxic actions of ECP are mediated chiefly, if not entirely,
by its ability to bind and disrupt membranes (17,18), rather
than its ribonucleolytic activity, which is 100-fold lower
than that of its homolog RNase A (19). More recent studies
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loop 32–39, and the Arg residues in binding to membrane
components (18,20,21). These studies, although valuable,
do not characterize these interactions directly because they
are limited to the environment of the Trp residue and the
positions mutated, and site directed mutagenesis may cause
structural changes that affect the binding of membrane
components in unexpected ways.
A recent study has shown the role of mammalian cell sur-
face glycosaminoglycans, specifically heparin sulfate proteo-
glycans, in ECP binding and endocytosis (22). It is well
known that certain sequence motifs in heparin binding pro-
teins (23) are responsible for the interaction with heparin.
Using site-directed mutagenesis and synthetic peptides it
was shown that the segment 34–38 of ECP (RWRCK) serves
as a specific heparin binding site (22). Nevertheless, these
studies were carried out with ECP fragments and the specific
heparin binding site of native ECP has not yet been charac-
terized structurally. Interestingly, it has been shown that ECP
binds to the glycocalix of eukaryote cells in cellular cultures
(17), suggesting that the tight binding to heparin might
modulate the cytotoxicity of ECP.
Using NMR spectroscopy, we present a study to structur-
ally characterize all these interactions more completely at a
residue level. NMR spectroscopy can, in principle, uncover
the participation of all residues in binding without perturbing
them. We have used dodecylphosphorylcholine (DPC)
micelles as a membrane mimetic, and a disaccharide mimetic
of heparin. DPC micelles were chosen because they have
zwitterionic character, which is common among lipids pres-
ent on the outer leaflet of human membranes (24,25).
Heparin is a linear, highly sulfated glycosaminoglycan that
is released by activated mast cells during inflammatorydoi: 10.1016/j.bpj.2010.02.039
FIGURE 1 Solution structure of ECP. Ribbon display of ECP with
secondary structure elements detailed. The molecule is composed of three
a-helices and six b-strands connected by different loops colored in purple
(loop 1: M0–T6), light green (loop 2: S17–R22), coral (loop 3: N32–
N39), magenta (loop 4: G56–N70), blue (loop 5: R75–R77), green (loop
6: I86–R97), and yellow (loop 7: R114–P123).
ECP Interactions by NMR 2703processes. We chose the disaccharide, 2S sulfated iduronic
acid (IdoA) 1-4 linked to 6S and NS sulfated glucosamine
(GlcN), as the shortest heparin repeating unit. Heparin-
derived disaccharides have been used in the past for this
purpose (26), and in some cases benefit has been obtained
from their reduced capacity to induce aggregation (27).
ECP has an exceptionally high conformational stability;
it is ~3.5 kcal/mol more stable than RNase A (4,28,29).
Because conformational stability was shown to be a determi-
nant of cytotoxicity in a series of RNase A variants (30), this
high conformational stability was thought to play a role in
the cytotoxicity of ECP. However, work on both a cytotoxic
RNase from chickens with Arg-rich loops (31), and more
recently, human ECP (32), has shown that peptides derived
from these proteins also possess potent cytotoxic activities
in the absence of stable tertiary structure. To better under-
stand the relationship between stability, structure, and
activity, we study the conformation of a cytotoxic ECP
peptide (residues 1–45) by NMR spectroscopy.MATERIALS AND METHODS
Materials
Dodecylphosphorylcholine-d38 (98% atom D) (DPC) was an Isotec product
obtained from Sigma-Aldrich (Madrid, Spain). The heparin sulfate disac-
charide, IdoA (2S) 1-4 linked to GlcNS (6S), was obtained from Sigma-
Aldrich (heparin disaccharide I-S sodium salt). 2,2,2-Trifluoroethanol-d3
(TFE) (>99.5% pure, NMR spectroscopy grade) was purchased from
Sigma-Aldrich.Peptide synthesis
The peptide sample containing the first 45 N-terminal residues of ECP
(ECP1–45) was chemically synthesized by Fmoc solid phase procedures
and purified by high performance liquid chromatography to 95% purity.
Cys residues at positions 23 and 37 in the native sequence were replaced
by Ser to avoid potential formation of inter- or intramolecular disulfide
bridges. The identity and sequence of the peptide was confirmed by matrix
assisted laser desorption/ionization time-of-flight mass spectrometry and
NMR spectroscopy.Puriﬁcation of recombinant 15N-ECP
The protein was expressed in Escherichia coli BL21(DE3) cells in minimal
medium with 15NH4Cl as the sole source for nitrogen and purified from
inclusion bodies as described previously (33).NMR samples
All NMR samples were recorded at 25C, pH 4.5 and contained 50 mM of
DSS as the internal chemical shift reference.ECP samples
A ~0.5 mM sample of 15N-ECP was initially prepared in 90% H2O/10%
D2O. Analogous aqueous solution samples of
15N-ECP were then prepared
in deuterated DPCmicelles, heparin sulfate disaccharide, and in the presence
of both DPC and heparin sulfate. The final concentrations were ~0.5 mM
15N-ECP and ~40 mM DPC for the sample containing DPC; ~0.25 mM
15N-ECP and ~0.25 mM heparin sulfate (1:1 complex) for the sample
with the disaccharide; and ~0.5 mM 15N-ECP, ~40 mM DPC, and
~0.5 mM heparin sulfate for the sample with the three compounds present.ECP1-45 peptide samples
The initial sample of ~1.1 mM ECP1-45 peptide was prepared in aqueous
solution of 90% H2O/10% D2O. Three subsequent samples of ~1.1 mM
ECP1–45 peptide in the same aqueous solution were prepared in 40%
TFE, 20 mM DPC micelles, and 20 mM DPC plus ~1 mM heparin sulfate
disaccharide, respectively. A fourth sample of ECP1–45 in 1:1 complex
with heparin sulfate disaccharide alone was prepared at concentration of
~2.5 mM. Another ~1.1 mM sample of the peptide was prepared in D2O
solution to evaluate amide proton exchange rates with the solvent. The final
pH reading for this sample was 4.5, with no correction for the isotope effect.Heparin sulfate disaccharide sample
A 1.6-mM sample of heparin sulfate disaccharide in D2O pH 4.5 was used to
record NMR spectra for the assignment of this molecule.NMR experiments
Series of 2D correlation spectroscopy (COSY), nuclear Overhauser effect
spectroscopy (NOESY), and total correlation spectroscopy (TOCSY)
spectra were acquired in a Bruker Avance 800 MHz spectrometer equipped
with a z-gradient cryoprobe at 25C. Standard pulse sequences were used.
Mixing times were 150 ms and 60 ms for NOESY and TOCSY experiments
recorded for ECP1–45, and 100 ms and 60 ms respectively for the 15N-ECP
sample. The same set of experiments were recorded in the heparin sulfate
disaccharide sample with mixing times of 200 ms and 60 ms for 2D NOESY
and TOCSY spectra, respectively. The spectra were processed with Topspin
1.3 (Bruker, Rheinstetten, Germany) and transferred to Sparky (34) for
further analysis. MolMol was used for molecular display (35).Biophysical Journal 98(11) 2702–2711
FIGURE 2 Conformational chemical shifts of ECP1–45
peptide: Dd values for 1Ha protons at pH 4.5 and 25C are
represented for the five different environments studied: (A)
aqueous solution; (B) 40% TFE; (C) 20 mM DPC; (D)
heparin sulfate disaccharide (1:1 complex with ECP1–45);
and (E) 20 mM DPC þ heparin disaccharide (1:1 complex
with ECP1–45).
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Helix populations were quantified from the 1Ha conformational chemical
shift (CCS) values as described (36). Thus, the DdHa differences (DdHa ¼
dHa
observed  dHarandom coil, ppm) averaged for all the helical residues were
divided by the DdHa value corresponding to 100% helix, 0.39 ppm (37),
and then multiplied by 100.RESULTS
The 1H NMR resonances of ECP and the peptide ECP1–45
in the different environments, TFE, DPC, and heparin sulfate
disaccharide were assigned using the standard procedures
(38). The assignments are essentially complete except for
a few isolated residues in the presence of DPC due to spectral
overlap or broadening.
ECP1–45 in water solution
We have used CCS of 1Ha protons to assess the secondary
structure content of the peptide in the different environments
tested (37). As shown in Fig. 2 A, the peptide in aqueous
solution is mainly unstructured and displays a low propensity
to form two a-helices spanning approximately residuesBiophysical Journal 98(11) 2702–2711R7–S17 and I25–R45. The boundaries of the first helix
match those of native helix a1 of ECP. However, the second
helix has remarkably lengthened the native helix a2 (C23–
N31) at its C-terminus by incorporating residues in loop 3
(N32–N39) and strand b1 (Q40–R45) of native ECP. The
helix populations are calculated to be 47% and 21% for the
first and second helices, respectively. Very few and weak
sequential 1HN-1HN nuclear Overhauser effects (NOEs)
were observed. The chemical shifts of the 1H side chains
are in the range of unstructured peptides and no evidence
for native or nonnative clusters are seen. In agreement with
these results, the 1D 1H NMR spectrum recorded at 25C,
pH 4.5 in a D2O sample, showed essentially complete
exchange of all amide hydrogens, providing evidence that
the protection afforded by helical structure of ECP1–45
against exchange is very weak.
ECP1–45 in TFE
The conformation of ECP1–45 was studied in 40% TFE
solution because it bears some resemblance to membrane
environments (39). The 1Ha CCS values show a significant
increase in the a-helical propensity. The boundaries for the
ECP Interactions by NMR 2705two helices are comparable to those in water solution, and
notably the second helix is also longer in 40% TFE. The esti-
mated helical populations are 76% for the first helix and 63%
for the second (Fig. 2 B); these values are 1.5- and 3-fold
higher than their populations in aqueous solution. In addition
to the 1Ha CCS values, the much higher tendency to form
the two helices is reflected by: 1), changes in 1HN Dd >
0.15 ppm for most residues in these segments; 2), an increase
in the number and intensities of sequential 1HN-1HN NOEs
especially in the segments Q4–I16 and T24–L44; and 3), the
observation of some unequivocal nonoverlapped 1Ha-1HN
(i, i þ 3) NOEs characteristic of helical conformation like
those between A8–F11, W10–I13 in the first helix, and
R28–N31, I30–Y33, W35–K38 in the second helix.
ECP1–45 in DPC micelles
The conformation of ECP1–45 was studied in 20 mM DPC,
which forms small uniform micelles that tumble rapidly
enough for solution NMR spectroscopy, and mimic more
realistically the membrane environment (40). As in 40%
TFE, the 1Ha CCS values (Fig. 2 C) of ECP1–45 in the pres-
ence of DPC micelles also show a significantly increased
tendency to form the two a-helices as compared to the
aqueous medium, with estimated helical populations of
71% and 47% for the first and second helices, respectively.
In the presence ofDPC, residuesN32–L44 also adopt a helical
conformation that extends native helix a2. Despite the spec-
tral line broadening induced by decreased mobility of the
complex, the backbone assignment is complete with the
exception of the 1Ha of R22. The poorer quality of the spectra
made it more difficult to identify (1Ha-1HN i, i þ 3) helical
NOEs, however, those between W10–I13 in the N-terminal
helix, and N31–R34 and N32–W35 in the central part of the
C-terminal helix could be unambiguously assigned. Thirteen
1HN-1HN NOE connections: R7–A8, A8–Q9, Q9–W10,
F11–A12, Q14–H15, H15–I16, I30–N31, R34–W35, R36–
S37, Q40–N41, N41–T42, T42–F43, and F43–L44 are
observed. The chemical shift perturbation (CSP) analysis
shows changes >0.15 ppm for the 1HN protons of R7, Q9,
F11, H15, I16, S17, L18, A26, A29, I30, R34, W35, K38,
N39, and F43, and the 1Ha of T6, I13, Q14, L18, S23, T24,
I25, A26, I30, Y33. Some side-chain protons also experience
important Dd (0.15–0.35 ppm), for example, those of W10,
Q14, H15, N32, and W35 to mention a few examples; Arg
side chains are also greatly perturbed.
ECP1–45 interaction with Heparin mimetic
Previous studies have established the ability of ECP to
interact with glycosaminoglycan structures, in particular
heparin (41). The heparin disaccharide resonances were
assigned and the measured chemical shifts are in agreement
with the reported values (42).
Spectra of ECP1–45 in the presence of the heparin sulfate
disaccharide are quite similar to those in water solution, witha low tendency to form two a-helices (Fig. 2 D). The
percentages of the helical contents are comparable to those
obtained in aqueous solution, with values of 50% and 24%
for the first and second helices, respectively. The boundaries
for both helices are similarly retained. Despite these similar-
ities, the NMR data provide conclusive evidence for the
binding of the peptide and the disaccharide, the sign of the
disaccharide intramolecular NOEs changes from positive in
the spectra registered in the absence of ECP1–45 to negative
in its presence due to their different tumbling regimes
(Fig. 3). Because the free disaccharide is a small and fast
rotating molecule, the NOEs have the opposite sign relative
to the diagonal peaks. However, when the interaction with
the peptide occurs, the different diffusional properties of the
larger complex are reflected in the sign of the NOEs that are
now the same as the diagonal.
No largeCSPs are detected for the peptide resonances in the
presence of the disaccharide or for the disaccharide reso-
nances in the presence of the peptide. Accordingly, no impor-
tant changes in the peptide NOEs are observed indicating that
carbohydrate-induced conformational changes are small.
Additionally, no intermolecular NOEs could be detected,
indicating the highly dynamic nature of the complex interface,
which promotes NOE quenching and makes their NMR
detection difficult (43,44). The two sets of resonances corre-
sponding to the a and b conformers of the GlcN unit are
still observed in the presence of the peptide, indicating that
no preferential conformer is trapped when the complex
is formed. CSPs are small for 1HN and 1Ha protons;
values >0.025 ppm are observed for the 1HN of F5, T6, R7,
Q9, W10, F11, A12, Q14, H15, I16, S17, L18, R28, I30,
N32, and K38, and the 1Ha of F5, R7, F11, I13, Q14, H15,
I16, I30, and N32. Residues from R34 to N39 have been sug-
gested to participate in the interaction of native ECP with
heparin based on characteristic patterns of basic and hydro-
phobic residues observed in glycosaminoglycan interacting
proteins and also identified in loop 3 of eosinophil-derived
neurotoxin (22). In addition, residues from the N-terminal
helix of ECP and Q14 at the active site have been proposed
to mediate the interaction based on docking simulations
(45). The chemical shifts of the aromatic side chains of F5,
F11, Y33, andW35 are similar to those in water solution lack-
ing the heparin disaccharide, as are the side chains of the
remaining residues in the segment R34-N39. In contrast, the
1H33 proton of W10 is clearly shifted toward higher field
~0.05 ppm, and the 1H chemical shift values of Qg, H321,
and H322 of Q14 are shifted upfield ~0.08, 0.13, and
0.04 ppm, respectively, suggesting the implication of these
side chains in the interaction.ECP1–45 in DPC micelles and heparin
sulfate disaccharide
To investigate whether the high affinity interaction of
ECP1–45 with heparin sulfate disaccharide displaces theBiophysical Journal 98(11) 2702–2711
FIGURE 3 ECP1–45 binding to disaccharide heparin
mimetic. Anomeric region of the 2D NOESY spectra
recorded in (left) the absence and (right) the presence of
the ECP1–45 peptide. (left) The different sign of the free
disaccharide NOEs (red) with respect to the diagonal of
the spectrum (blue) is characteristic of small and fast
rotating molecules. (right) The same sign of the bound
disaccharide NOEs (blue) with respect to the diagonal
(blue), reflects the diffusional properties of the larger
complex when the interaction with the peptide occurs.
2706 Garcı´a-Mayoral et al.interaction with DPC, which would indicate common/
partially superimposing interfaces, we added the disaccha-
ride to our previous sample in DPC solution. The spectra
showed the broad resonances characteristic of the peptide-
micelle complex, and the spectra could be easily assigned
using ECP1–45 assignments in DPC micelles. The 1Has of
Q14 and R22 could not be identified. The CCSs are similar
to those in the DPC medium alone (percentages of 71% and
47% for both helices, Fig. 2 E), thus the increased helix pop-
ulation induced by DPC is not reduced by adding the heparin
mimetic. The chemical shift differences provoked in ECP1–
45 by the disaccharide in the presence of DPC are
similar to those detected in the absence of DPC. In general,
the CSPs are small, with chemical shift changes>0.025 ppm
occurring for 1HN protons of residues Q4, F5, A8, W10,
F11, I13, H15, T24, I30, and N32, and 1Ha of P3, Q4, F5,
T6, R7, A12, I13, H15, S17, and N19. Significant chemicalBiophysical Journal 98(11) 2702–2711shift changes are found for the 1H31, 1Hd1, and 1H33 of W10
(0.05, 0.05, 0.09 ppm, respectively). These changes match
those observed with the disaccharide alone quite well, sug-
gesting that the interaction surfaces with DPC and heparin
are not mutually exclusive.ECP interaction with DPC micelles
Next, 15N-HSQC spectra of native, full length, 15N-labeled
ECP in aqueous solution (Fig. 4 A) and in DPC micelles
(Fig. 4 B) were recorded and assigned based on recently pub-
lished data (4) and corroborated at these solvent conditions
using 3D 15N-NOESY-HSQC spectra. Using the CSPs
induced in 1HN and 15N chemical shifts on binding to
DPC, we have mapped the residues most affected on the
molecule surface (Fig. 5, A and B). The interaction surface
is well defined and constituted by residues belonging to
FIGURE 4 15N-HSQC spectra of native ECP, pH 4.5
and 25C, in different conditions. (A) Aqueous solution
and the presence of (B) 40 mM DPC, (C) heparin sulfate
disaccharide (1:1 complex), and (D) 40 mM DPC and
heparin sulfate disaccharide (1:1 complex).
ECP Interactions by NMR 2707different loops, Q4-T6 in loop 1, N32-R36 in loop 3, T46 in
the segment connecting strand b1 with helix a3, and N87,
A90-I93, C96, R97 in loop 6. The 1H31 side-chain proton
of W35 experiences one of the largest variations observed
in the HSQC spectrum corroborating its crucial role in the
process. These three protein loops project outward on the
same face of the molecule with residues in loop 3 stacked
in between loops 1 and 6. W35 side chain is hyperexposed,
which facilitates its insertion into the micelle and stabiliza-
tion of the complex interface environment (46).
ECP interaction with heparin mimetic in the
presence of DPC micelles
ECP strongly interacts with heparin sulfate oligosaccharides
(22). At concentrations suitable for NMR spectroscopy, we
observed that the ECP sample precipitated instantly on add-
ing the heparin sulfate disaccharide, which thwarted efforts
to characterize their complex under these conditions. The
15N-HSQC spectrum of this sample (Fig. 4 C) indicates
that no native ECP is left in solution. Therefore, the disac-
charide was added to a sample containing ECP and DPC.
No precipitation was observed, and the effects of the addition
of the disaccharide were analyzed by the chemical shift
changes induced in the 15N-HSQC spectrum of ECP
recorded in these conditions with respect to the DPC solution
alone (Fig. 4D). By using the average 1HN and 15N chemical
shift values to map the interaction surface, the biggest pertur-
bations were found to affect residues Q4 in loop 1, A8 and
F11-Q14 in helix a1, Y33-R36 in loop 3, Q40-L44 in strand
b1, C62, H64, R66 in loop 4, R75, R77 in loop 5, C83, L85
in strand b3, and H128-D130 in strand b6 (Fig. 5, C and D).
The side chain 1H31 protons of W10 and W35 are also
considerably perturbed (0.11 and 0.14 ppm, respectively).
CSPs implicate a large number of Arg residues in binding
the disaccharide; Arg residues are common at heparin
binding domains due to their hydrogen bonding propensityand strong electrostatic interactions with sulfate groups (47).
Although residues in loop 3 are common to the interaction
surface with DPC, residues in the C-terminal part of the first
helix are exclusively perturbed by the disaccharide, most
notable the catalytically relevant residue Q14, whereas
loop 1 is affected selectively by DPC binding.DISCUSSION
Despite recent progress, we are still far from understanding
completely the mechanism of action of cytotoxic RNases.
The elucidation of their activities requires structural studies
with targets. To characterize the structural bases of the cyto-
toxic activity related to ECP interaction with membranes,
we have used NMR to study the behavior of ECP and the
N-terminal-derived peptide ECP1–45 in water and in media
that mimic the membrane environment of eukaryote cells.
Residues 1–45 of ECP were detected by an algorithm as
having a high propensity to be bactericidal (48) and were
shown to maintain most of the membrane-destabilizing and
antimicrobial activities of ECP (32). This suggests that this
segment probably constitutes the main functional domain
of ECP.
ECP1–45 conformational preferences and binding
to DPC membrane mimetic
We have studied the ECP1–45 peptide to gain insight into
the relationships between structure, stability and biological
activities of ECP. Secondary chemical shifts and H/D
exchange data provide clear evidence that the ECP1–45
peptide, although mainly unstructured in water, forms two
partially populated a-helices separated by a flexible turn
(L18–T24). Because the conformational restraint imposed
by the disulfide bridge C37–C96 of native ECP is not present
in the peptide, the substitution of C37 by S37 may allow the
second helix to become longer. The second helix is lessBiophysical Journal 98(11) 2702–2711
FIGURE 5 Interaction surfaces of native ECP with DPC
and heparin mimetic. (A) Chemical shift perturbation
map for DPC displayed on the surface of ECP; red Dd >
0.08 ppm, orange 0.05<Dd< 0.08. (B) Residues involved
in the interaction of ECP with DPC are colored according
to the groups described in the text, loop 1 (violet), loop 3
(coral), and loop 6 (green). (C) Chemical shift perturbation
map for heparin disaccharide displayed on the molecular
surface of ECP; red D d > 0.08 ppm, orange 0.05 <
Dd < 0.08 ppm. (D) Residues involved in the interaction
of ECP with heparin sulfate disaccharide are colored
according to the groups described in the text, A8–Q14
(green), Y33–R36 (red), Q40–L44 (yellow), H128–D130
(blue). Other affected residues are pink. (E and F) Simulta-
neous representation of the interaction surface of ECP with
DPC and heparin mimetic. Residues in blue are common to
the interaction with DPC and heparin disaccharide, resi-
dues in yellow belong exclusively to the interaction surface
with DPC, and residues in violet correspond exclusively to
the interaction surface with heparin sulfate disaccharide.
2708 Garcı´a-Mayoral et al.populated in all the environments studied, although its
helical content rises substantially in 40% TFE and DPC
micelles. An overall increase in helical structure was also
observed by CD spectroscopy for ECP1–45 in the presence
of SDS micelles or bacterial membrane components (32).
Interestingly, the adopted helix-turn-helix motif is common
in many peptides that interact with membranes, including
a variety of antimicrobial peptides (49–51).
Previous studies have already identified some residues in
the fragment 1–45 as important for the interaction with
membranes. In particular, the highly solvent-exposed W35
and nearby arginine residues, R34 and R36, participate
actively in membrane interactions. By NMR, we corroborate
that these residues are involved, and we also find additional
residues participating in membrane interactions. Most form
clusters of positively charged and aromatic residues (R7,
F11, H15, in helix a1, and R34, W35, K38, F43 in helix
a2) and aliphatic chains (A26, A29, I30 in helix a2)
that are concentrated on opposite helical faces. This orienta-
tion suggests that they are favorably positioned to formBiophysical Journal 98(11) 2702–2711electrostatic and hydrophobic interactions with the mem-
brane (52).Insights into the capacity of ECP to bind
and disrupt membranes
Our NMR analysis shows that the interaction surface of
ECP with DPC micelles is well-defined, involving loops 1
(R1–T6), 3 (N32–N39), and 6 (I86–R97) in the interactions
(Fig. 5, A and B). These three loops point toward the same
face of the protein; loop 3 is sandwiched by loops 1 and 6
in a spatial disposition that may strengthen binding. Some
Gln and Asn side chains (Q4, N32, Q91) and many Arg
side chains have high degrees of solvent exposure and are
likely to be involved in H-bond formation. For example,
R97 is also solvent exposed and could assist Args in loop
3 to bind DPC micelles. Interestingly, R97 corresponds to
the only polymorphism known. The R97T variant implies
a new glycosylation site and this variant is markedly less
cytotoxic (46). On enzymatic deglycosylation, the R97T
ECP Interactions by NMR 2709variant recovers its cytotoxicity, suggesting that glycosyla-
tion can cover a key region for cytotoxicity (21). Recent
studies suggest that ECP activity is enhanced by deglycosy-
lation during eosinophil activation (53). Nitration of tyro-
sines is another posttranslational modification recently
identified for eosinophil secretory proteins and associated
with eosinophil maturation. Tyr nitration occurs in ECP
exclusively on Y33 (54) and may modify its interacting pro-
perties. The aromatic ring of Y33 is expected to contribute
modestly to membrane binding as it is buried in some
NMR structures (4). Nitration likely favors the more exposed
conformation of Y33 seen in other NMR solution structures
and could position it to interact favorably with positively
charged choline moieties in membranes.The groove between helix a1 and loop 3 of ECP
can accommodate heparin mimetics
The oligomerization of heparin-binding proteins on the
heparin chain is a common event (55,56). The observed
sample precipitation when ECP was mixed with a solution
containing the heparin sulfate disaccharide precluded the
study of the interaction between full-length ECP and the
heparin disaccharide. Instead, ECP1–45 plus disaccharide,
and ECP in DPC micelles plus this disaccharide were
studied. The binding to ECP1–45 is in general agreement
with that observed for ECP, although we also found impor-
tant differences. Residues in the stretch Q9–H15 participate
in binding in both ECP and ECP1–45, however, no signifi-
cant changes occur in the peptide for residues in loop 3 of
ECP. Among the aromatic groups, F5, W10, and F11 are
implicated in binding. R7, W10, F11, Q14, and H15 are
mainly localized on one face of the first helix. It is conceiv-
able that the aromatic residues in this stretch, together with
F5 probably playing the role of W35 in native ECP, form
a hydrophobic platform in one side of the helix. R7 can con-
tribute electrostatically to the interaction. Because ECP1–45
retains nearly all of the bactericidal activity of the whole
protein, the differences noted above may account primarily
for the partially retained membrane depolarization capacity
of the peptide (32). This data also indicates that the tertiary
structure of ECP and remarkably high conformational
stability are not required for these functions. Therefore the
real physiological role of the remarkably high conforma-
tional stability of ECP is a mystery. As a working hypothesis
for designing future studies, we suggest that the high confor-
mational stability of ECP might be required for storage in
eosinophil granules.
Concerning ECP, the residues identified to be involved
directly or indirectly in heparin binding can be grouped
into four main groups shown in Fig. 5, C and D: 1),
A8–Q14 in helix a1; 2), Y33–R36 in loop 3; 3), Q40–L44
in strand b1; and 4), H128–D130 in strand b6. Whereas
the interaction of residues in loop 3 of ECP with heparin
mimetics was described previously (22), those in the otherthree groups have been identified in this study for what we
believe to be the first time. Examining these results in the
context of the ECP solution structure, we are able to propose
a model for the interaction. Residues in loop 3 of ECP, are
spatially close to the second half of helix a1, and these
two regions face each other defining a groove that would
accommodate the sugar moiety. This groove is bound on
top by residues in strand b1. The opposite face of the helix
a1 is close to residues of strand b6.
Two Trp residues (W10 and W35) are found in the groups
mentioned above. As W35 is highly solvent-exposed
whereas W10 is mainly buried, it is expected that the W35
contribution to the binding affinity will be higher. The two
Arg residues adjacent to W35 probably contribute to the
binding affinity by ion-pairing spatially with negatively
charged sulfate or carboxylate groups of the disaccharide.
Such interactions are common for Arg-rich membrane pene-
trating peptides (57). The side chains of W10, Q14, and Y33
are near each other and oriented toward the interior of the
cavity. Actually, the perturbation observed for the 1HN of
Q14 is one of the largest in the spectra suggesting that this
residue is involved in the binding process. In ECP, Q14 is
close to N41 and F43; this would explain the perturbations
observed for residues in strand b1. F11 is on the side of
the helix pointing away from the cavity and toward residues
in strand b6, and in particular its side chain is near that of
L129, which is also near strand b1. These contacts suggest
an explanation for the changes in this region.
Some of the residues that we have found to participate in
the binding of ECP to heparin disaccharide (Q14, Q40, T42,
L129) are located at RNA substrate binding sites. Among the
catalytic residues, H128 seems to participate in disaccharide
binding. Consequently some of the residues involved in the
ribonucleolytic activity of ECP also participate in ECP
binding to heparin, and this can account for the decreased
ribonucleolytic activity with increasing heparin concentra-
tions (45).
Interestingly the set of residues in the protein surface that
are in contact with heparin disaccharide only partly overlap
that involved in DPC interactions (Fig. 5, E and F). Because
the broadening of the NMR signals resulting from the forma-
tion of the large complex of ECP with the micelles is
retained when the heparin disaccharide is present, and also
additional chemical shift perturbations are observed (partic-
ularly those in helix a1), it is likely that ECP binds to
membranes and heparin simultaneously. This could have
implications for the efficient internalization of ECP in mem-
branes (57), host cytotoxicity, and its ability to modulate the
immune system. The residues binding to DPC micelles,
which mimic the outer leaflet of human membranes, are
largely those that are also implicated in binding to bacterial
membrane and cell wall components (58). This suggests that
it will be difficult to engineer ECP variants that do not harm
host cells yet retain potent toxicity for parasites, bacteria,
and virus.Biophysical Journal 98(11) 2702–2711
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